CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 320 enrolled
Drug / intervention
VRVg 2 +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03145766
NCT03145766Phase 2Completed
CompareCT.gov

Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free When Administered According to a Simulated Rabies Post-exposure Regimen in Healthy Adults

Sanofi Pasteur, a Sanofi Company·interventional·Posted May 9, 2017·Updated Apr 19, 2022

In Brief

A Phase 2 clinical trial evaluating VRVg 2, VRVg 1, and 2 other interventions for Rabies Virus. Completed, enrolled 320 participants across 5 sites.

Detailed Summary

This multicenter, observer-blind, controlled, randomized, Phase II study was designed to evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRabies Virus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 9, 2017
Enrollment StartApr 17, 2017
Primary CompletionJan 8, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.1 years ago

Interventions

VRVg 2biological

Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free

VRVg 1biological

Initial formulation of Purified Vero Rabies Vaccine Serum Free

Imovax Rabiesbiological

Purified inactivated rabies vaccine prepared on human diploid cell cultures

VRVg 2biological

Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free

VRVg 2biological

Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free

Human Rabies Immunoglobulins (HRIG)biological

Commercialized formulation of HRIG